Accessibility Tools

New hyaluronic acid fillers aim to correct midface volume loss

The pivotal clinical trial leading to approval of the new filler was conducted at 15 sites in North America. It included 235 patients who were treated to correct midface volume deficit and 47 untreated controls. Eligible patients had moderate, significant or severe midface volume deficit as assessed using a six-point validated rating scale.

Patients in the treatment group received injections into one, two or three subregion treatment areas (zygomaticomolar, anteromedial cheek and submalar) and could receive a touch-up one month later to optimize the results. Median injection volume was 6.6 mL (range 1.1 mL to 13.9 mL). Follow-up visits were scheduled quarterly through 24 months. – See more at:


Read More